MRK — Merck & Co., Inc.

Merck & Co., Inc. (MRK) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $16.3 billion, a year-over-year increase of 5% (3% growth excluding foreign exchange impacts).
• Oncology Sales: KEYTRUDA family generated $8 billion, up 8%, driven by strong demand in metastatic and earlier-stage cancers.
• Animal Health Sales: Increased by 6%, with livestock sales up 8% and companion animal sales up 4%.
• Gross Margin: 81.9%, slightly down by 0.3 percentage points.
• Operating Expenses: $15.2 billion, including a $9 billion one-time charge related to the acquisition of Cidara Therapeutics.
• Earnings Per Share (EPS): Reported loss of $1.28, impacted by the Cidara charge; non-GAAP EPS guidance for 2026 is projected between $5.04 and $5.16.

2. Strategic Updates and Business Highlights:

• Pipeline Progress: FDA approved IDVYNSO for HIV-1 treatment and granted priority review for I-DXd for lung cancer.
• New Product Launches: Over 20 new products anticipated, with significant potential for blockbuster status.
• Acquisition Strategy: Planned acquisition of Terns Pharmaceuticals, expected to enhance the oncology pipeline with TERN-701 for chronic myeloid leukemia.
• Commercial Structure Evolution: Introduction of a new business unit model to enhance focus and agility in therapeutic areas.
• AI Initiatives: Partnership with Google Cloud to leverage AI capabilities for improved productivity and innovation.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Narrowed to $65.8 billion to $67 billion, reflecting 1% to 3% growth, with a positive foreign exchange impact.
• Operating Expenses Guidance: Expected between $36 billion and $36.8 billion, excluding potential acquisitions.
• EPS Guidance: Non-GAAP EPS anticipated between $5.04 and $5.16, factoring in the impact of the Cidara acquisition and ongoing investments.

4. Bad News, Challenges, or Points of Concern:

• GARDASIL Sales Decline: Decreased by 22% due to lower demand in key markets, including China and Japan.
• OHTUVAYRE Sales Impact: Adverse effects from CMS reimbursement changes and Medicare deductible resets, though recovery is expected in the second half of the year.
• Negative EPS Impact: The one-time charge from the Cidara acquisition significantly affected reported earnings.
• Competitive Pressures: Ongoing competition in oncology and infectious diseases, particularly with the recent approval of competing HIV treatments.

5. Notable Q&A Insights:

• Pipeline Confidence: Executives expressed optimism about upcoming clinical trial results, particularly for WELIREG and its potential to provide overall survival benefits.
• Business Development Strategy: Merck is focused on unmet scientific needs rather than specific therapeutic areas, with a deal size sweet spot of $1 billion to $15 billion.
• TL1A in Immunology: There is a strategic focus on TL1A as a potential cornerstone in immunology, with plans to explore combination therapies.
• HIV Program Commitment: Strong commitment to advancing the HIV pipeline, with a focus on innovative treatment regimens that could enhance patient outcomes.

Overall, Merck's Q1 2026 results reflect solid revenue growth driven by oncology and animal health, alongside strategic advancements in its pipeline and commercial structure. However, challenges in specific product sales and the impact of acquisitions on earnings present areas of concern moving forward.